Počet záznamů: 1
Anionic pregnane compounds, method for their producing and use of them
- 1.
SYSNO ASEP 0435943 Druh ASEP P - Patent Zařazení RIV P - Patent nebo jiný výsledek chráněný podle zvláštních právních předpisů Název Anionic pregnane compounds, method for their producing and use of them Tvůrce(i) Šťastná, Eva (UOCHB-X) ORCID
Chodounská, Hana (UOCHB-X) RID, ORCID
Pouzar, Vladimír (UOCHB-X)
Kapras, Vojtěch (UOCHB-X)
Cais, Ondřej (FGU-C)
Vyklický ml., Ladislav (FGU-C) RID, ORCID, SAI
Kohout, Ladislav (UOCHB-X)Celkový počet autorů 7 Rok vydání 2014 Využití jiným subj. A - Pro využití výsledku jiným subjektem je vždy nutné nabytí licence Lic. popl. A - Poskytovatel licence požaduje licenční poplatek Číslo pat.spisu EP2313424 Datum udělení 23.04.2014 Vlastník patentu Ústav organické chemie a biochemie AV ČR, v. v. i. - Fyziologický ústav AV ČR, v. v. i Kód vydavatele patentu EPO_1 - European Patent Office Munich, The Hague, Berlin, Vienna, Brusselshttp://www.epo.org/ Využití A - Pouze udělený (dosud nevyužívaný) patent nebo patent využívaný jeho vlastníkem Jazyk dok. eng - angličtina Klíč. slova NMDA ; neurosteroid ; neuroprotection Vědní obor RIV CC - Organická chemie CEP GAP303/12/1464 GA ČR - Grantová agentura ČR Institucionální podpora UOCHB-X - RVO:61388963 ; FGU-C - RVO:67985823 Anotace This invention relates to pregnane anionic compounds of general formula I in which R1 is ester group, which is able to form ion such as sulfate, pyridinium sulfate, hemisuccinate etc., R2 is hydrogen atom in alpha or beta configuration, and R3 is ester group, as is acetoxy group, nicotinoyloxy group etc., and their pharmaceutically acceptable salts. Compounds of general formula I are preferably produced from the diol of formula II or diol of formula VIII, which are converted according to described sequence of reactions, to compounds of general formula I, in which R1 is ester group, which is able to form ion such as sulfate, pyridinium sulfate, hemisuccinate etc., R2 is hydrogen atom in alpha or beta configuration, and R3 is ester group. The compounds of general formula I are useful as active ingredients for production of pharmaceuticals for the treatment of neurological and psychiatric diseases and conditions associated with excessive activation of NMDA receptors such as neuroprotective agents against excitotoxic damage of the central nervous system (CNS), conditions associated with excessive activation of NMDA-subtype glutamate receptors or, where this type of receptor is involved in the creation or during the certain mental and neurological diseases, in particular concerning the traumatic and hypoxic damage Io nervous tissue in the central nervous system diseases, such as Alzheimer's, Huntington's and Parkinson's disease, also in cognitive disorders in aging; the other indications could be tardive dyskinesia, amyotrophic lateral sclerosis, olivopontocerebellar degeneration, neurological problems1 associated with AIDS infection, allergic encephalomyelitis, and for medication of epilepsy, anxiety, depression, schizophrenia, chronic pain and drug addiction. Pracoviště Ústav organické chemie a biochemie Kontakt asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Jana Procházková, Tel.: 220 183 418 Rok sběru 2015 Elektronická adresa http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=2313424B1&KC=B1&FT=D&ND=5&date=20140423&DB=EPODOC&locale=en_EP
Počet záznamů: 1